Destina Genomics, a biotechnology company specializing in advanced molecular diagnostics, has announced the appointment of Jane Theaker as its new Chief Executive Officer. The leadership change comes as part of a broader strategic realignment following Mecwins’ recent equity investment in the company.
In July 2025, Mecwins acquired approximately 20% of Destina Genomics, as a strategic partnership, underscoring its confidence in Destina’s technology and growth trajectory. The deal is expected to foster deeper collaboration between the two companies in the field of diagnostics and RNA detection.
As part of this agreement, Óscar Ahumada, General Manager of Mecwins, will join Destina Genomics’ Board of Directors. Serving as Mecwins’ representative, Ahumada will contribute to guiding Destina’s strategic direction and ensuring alignment between the two firms.
“I am delighted to take on the role of CEO at such a pivotal moment for Destina,” said Theaker. “With Mecwins’ support and expertise, we are well positioned to accelerate the development and deployment of our diagnostic platforms, expand into new markets, and deliver real impact for healthcare providers and patients.”
Óscar Ahumada highlighted the significance of Mecwins’ investment: “Joining the board allows us to play an active role in shaping Destina’s future. We believe in the company’s technology and its potential to transform diagnostics, and we are excited to support its next stage of growth.”
Founded in Edinburgh and based in Granada, Destina Genomics has developed proprietary chemistry for the detection of nucleic acids and microRNAs, enabling highly accurate and accessible diagnostic solutions. With new leadership, a strengthened governance structure, and Mecwins’ backing, the company is preparing to expand its innovation pipeline and commercial reach across Europe and beyond.
